SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-207722
Filing Date
2021-07-02
Accepted
2021-07-02 16:55:16
Documents
13
Period of Report
2021-06-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d194551d8k.htm   iXBRL 8-K 32689
2 EX-3.1 d194551dex31.htm EX-3.1 5436
  Complete submission text file 0001193125-21-207722.txt   171562

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gthx-20210630.xsd EX-101.SCH 2909
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20210630_lab.xml EX-101.LAB 19658
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20210630_pre.xml EX-101.PRE 12326
6 EXTRACTED XBRL INSTANCE DOCUMENT d194551d8k_htm.xml XML 3685
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 211071029
SIC: 2834 Pharmaceutical Preparations